Instil Bio, Inc.

Equities

TIL

US45783C2008

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
10.6 ^USD	+1.92%		-0.38%	+39.11%

Apr. 26	Instil Bio, Inc. Announces Board Changes	CI
Apr. 15	North American Morning Briefing : Stock Futures -2-	DJ

Instil Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 13, 2023 at 05:03 pm EST

Instil Bio, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 67.43 million compared to USD 56.22 million a year ago. Basic loss per share from continuing operations was USD 10.4 compared to USD 8.6 a year ago.
For the nine months, net loss was USD 143.16 million compared to USD 169.33 million a year ago. Basic loss per share from continuing operations was USD 22 compared to USD 26.2 a year ago.

Latest news about Instil Bio, Inc.

Instil Bio, Inc. Announces Board Changes	Apr. 26	CI
North American Morning Briefing : Stock Futures -2-	Apr. 15	DJ
Jefferies Downgrades Instil Bio to Hold From Buy	Apr. 12	MT
Instil Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Instil Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Instil Bio, Inc. Enters into Agreement with A Collaboration to Conduct Preclinical Manufacturing Feasibility Studies in the ITIL-306 Program	Jan. 16	CI
Instil Bio, Inc. Announces the Closure of Its UK Manufacturing and Clinical Operations	Jan. 16	CI
Instil Bio, Inc.(NasdaqCM:TIL) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Instil Bio Says 1-for-20 Reverse Stock Split to Take Effect on Dec. 7	Dec. 06	MT
Instil Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Instil Bio, Inc.(NasdaqCM:TIL) dropped from S&P Global BMI Index	23-09-18	CI
Instil Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
HC Wainwright Initiates Instil Bio With Buy Rating, $2 Price Target	23-06-29	MT
Instil Bio, Inc. Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference	23-06-26	CI
Instil Bio, Inc.(NasdaqGS:TIL) dropped from Russell Small Cap Comp Value Index	23-06-23	CI
Instil Bio, Inc.(NasdaqGS:TIL) dropped from Russell 3000 Index	23-06-23	CI
Instil Bio, Inc.(NasdaqGS:TIL) dropped from Russell 3000E Index	23-06-23	CI
Instil Bio, Inc.(NasdaqGS:TIL) dropped from Russell Small Cap Completeness Index	23-06-23	CI
Instil Bio, Inc.(NasdaqGS:TIL) dropped from Russell 2500 Index	23-06-23	CI
Instil Bio, Inc.(NasdaqGS:TIL) dropped from Russell 2000 Index	23-06-23	CI
Instil Bio, Inc.(NasdaqGS:TIL) dropped from Russell 3000E Value Index	23-06-23	CI
Instil Bio, Inc.(NasdaqGS:TIL) dropped from Russell 3000 Value Index	23-06-23	CI
Instil Bio, Inc.(NasdaqGS:TIL) dropped from Russell 2000 Value Index	23-06-23	CI
Instil Bio, Inc.(NasdaqGS:TIL) dropped from Russell 2000 Dynamic Index	23-06-23	CI
Instil Bio, Inc.(NasdaqGS:TIL) dropped from Russell 2500 Value Index	23-06-23	CI

Chart Instil Bio, Inc.

Duration

Period

More charts

Company Profile

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.6 USD

Average target price

27.67 USD

Spread / Average Target

+161.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INSTIL BIO, INC.	+39.11%	68.94M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research